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Serial changes in oxidized low-density 
lipoprotein associated with culprit vessel 
in ST-elevation myocardial infarction 
– a promising marker? [28]
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RESUMO
Variações longitudinais de lipoproteínas 
de baixa-densidade oxidadas associadas 
à artéria “culpada” no enfarte do 
miocárdio com elevação ST – um 
marcador promissor?
Objectivo: Estudaram-se as variações de 
lipoproteínas de baixa densidade oxidadas 
(oxLDL) na fase aguda do enfarte do miocárdio 
e ao longo do período de recuperação, e 
ainda explorar as relações deste marcador 
com a gravidade da doença coronária. 
Foram avaliados 50 doentes com enfarte do 
miocárdio com elevação de ST nas primeiras 
24h de evolução (grupo AMI). Para efeitos 
de comparação estabeleceu-se um grupo de 
25 voluntários saudáveis (grupo referência). 
Os doentes do grupo AMI foram seguidos 
imediatamente após o enfarte do miocárdio 
(nas primeiras 24h de evolução, antes da 
angiografia e administração de inibidores das 
glicoproteínas IIb/IIIa), e ainda ao longo do 
período de recuperação, 48h e 40 dias após 
a intervenção. As concentrações de oxLDL 
foram medidas por ELISA, e verificou-se 
que estavam significativamente elevadas 
nos doentes com AMI na fase aguda (Dia 
0), decrescendo progressivamente ao longo 
do período de recuperação. Verificou-se 
ainda que as concentrações de oxLDL estão 
ABSTRACT
The aim of the present study was to investigate 
variations in oxidized LDL (oxLDL) at the 
onset of acute myocardial infarction (AMI) 
and over the recovery period, exploring their 
relationship with coronary disease severity. A 
follow-up of 50 AMI patients was evaluated 
against 25 healthy volunteers (reference 
group). The AMI patients were evaluated 
at three time points: at admission before 
the administration of IIb/IIIa inhibitors 
and angioplasty, and two and 40 days after 
intervention. Plasma oxLDL concentrations 
were measured by ELISA. oxLDL was found 
to be significantly higher in AMI patients in 
the acute phase relative to reference levels, 
decreasing progressively over the recovery 
period. The results also demonstrated that 
oxLDL levels were decreased in patients with 
the left circumflex artery (LCX) as culprit 
vessel compared to the left anterior descending 
coronary (LAD) or right coronary artery (RCA). 
The results highlight a significant increase in 
oxLDL concentration related to coronary artery 
disease severity, as conditions such as LCX 
lesions are usually associated with a favorable 
prognosis, contrasting with LAD-associated 
conditions that can compromise large areas 
of myocardium. The results thus suggest that 
oxLDL may constitute a promising marker in 
assessment of AMI evolution. 
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Several studies have shown a correlation 
between plasma levels of oxLDL products 
and the presence and/or severity of coronary 
artery disease (CAD)(3-5). However, the clinical 
importance of this marker remains to be 
established, both at the onset of acute episodes 
and at different stages of disease evolution, as 
does its possible prognostic value.
The objective of this study was to investigate 
serial changes in oxLDL in the plasma of patients 
with coronary artery disease immediately after 
acute myocardial infarction and during the 
recovery period, and to explore the relation of 
this marker with disease severity and extent.
METHODS
Study groups
A total of 75 subjects (16 women and 59 men) 
were recruited at the Cardiology Department of 
Santa Marta Hospital, Lisbon. Among them, 
50 patients with acute myocardial infarction 
constituted the myocardial infarction (AMI) 
group. The subjects in this group all had ST-
elevation myocardial infarction (ST-element 
changes and creatine kinase >3 times normal) 
in the first 24 hours of evolution and underwent 
INTRODUCTION
Coronary plaque disruption, with consequent platelet aggregation and thrombosis, is the 
most important mechanism by which athero - 
s clerosis leads to acute ischemic syndromes such 
as acute myocardial infarction (AMI).
The oxidative hypothesis of atherosclerosis 
recognizes oxidative stress and subsequent mo d - 
i fication of low-density lipoprotein (LDL) as a 
central paradigm. The transport of native and 
oxidized LDL (oxLDL) across the endothelium 
into the artery wall is therefore an important 
initiating event(1).
Human studies have confirmed that oxLDL 
and oxidized lipid by-products are present 
within atherosclerotic plaques(2). The oxidation of 
LDL has been associated with atherothrombosis, 
as it promotes apoptosis of endothelial cells 
and macrophages and upsets the anticoagulant 
balance in endothelium, which in turn stimulates 
tissue factor production and promotes platelet 
adhesion, facilitating plaque destabilization and 
erosion(2). oxLDL therefore plays an important role 
in initiating and maintaining the inflammatory 
process in atherosclerotic lesions(2), and levels of 
oxLDL in blood appear to be associated with this 
process.
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diminuídas ao longo do período de estudo 
nos doentes cujo vaso culpado foi a artéria 
coronária circunflexa relativamente à artéria 
coronária direita ou ascendente. Os resultados 
apontam para um aumento importante das 
concentrações de oxLDL relacionado com a 
gravidade da doença coronária, uma vez que 
condições clínicas como lesões culpadas na 
artéria coronária circunflexa estão usualmente 
associadas a prognósticos mais favoráveis, 
por contraste com condições associadas a 
lesões na coronária direita, as quais provocam 
danos em áreas mais vastas do miocárdio. 
Desta forma, os resultados sugerem que as 
concentrações de oxLDL poderão constituir 
um marcador promissor na avaliação da 
evolução do enfarte agudo do miocárdio.
Palavra-chave 
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Statistical analysis
Data were summarized as mean and standard 
error (SE) for continuous variables and as 
proportions for categorical variables. Non-
continuous variables were analyzed using a 
2x2 table and Fisher’s exact test. Differences 
between healthy subjects and AMI patients at 
each time point were compared using a general 
linear model ANOVA.
Plasma oxLDL concentrations were studied 
in AMI patients by modeling them as a response 
variable over time, since observations on the same 
individual are inter-correlated. A logarithmic 
transformation of oxLDL values was applied. 
The time variable was categorized as 1, 2 and 3 
for the three consecutive samplings (Days 0, 2 
and 40), and hence changes in oxLDL per time 
unit should be interpreted as changes between 
these consecutive samplings. A linear mixed 
effects model was used to fit oxLDL variations 
over time and the association with biochemical 
and disease severity indicators and medication 
data. The model takes into account that for each 
patient, measures at the three different time 
points are associated. The model intercept gives 
the mean oxLDL level in the acute phase and 
estimates the differences in mean slopes between 
study time points.
Values of p<0.05 were considered statistically 
significant. The calculations were performed 
using SPSS (version 10.0) and R (version 2.5) 
software.
RESULTS
Characteristics of the study groups
The demographic characteristics and baseline 
clinical data are listed in Table I. Since coronary 
disease risk factors and comorbidities were ex-
clusion criteria in the REF group, subjects en-
rolled inevitably differed from patients (Table I).
Prior to the myocardial infarction only 12 
patients were not taking any kind of medication. 
After admission, in-hospital medication in-
cluded aspirin (75%), beta-blockers (11%), 
ACE inhibitors (61%), statins (36%) and 
platelet inhibitors (68%). During follow-up all 
patients took platelet inhibitors (clopidogrel, 
71%; aspirin, 75%) in addition to the above 
medication.
primary percutaneous transluminal coronary 
angioplasty as reperfusion therapy.
A reference group (REF) of 25 healthy non-
smoking volunteers with no previous history of 
coronary disease or chest discomfort was also 
established to help with interpretation of baseline 
lipid oxidation. These volunteers did not undergo 
coronary angiography.
Subjects aged over 90 years or with significant 
comorbidities including peripheral artery di-
sease or carotid artery disease, known history of 
malignancy or infectious diseases, chronic renal 
insufficiency or previous AMI in the last five 
years, were excluded.
Detailed in-hospital data were recorded, in-
cluding age; gender; coronary risk factors (smok-
ing, diabetes, hypertension, hyperlipidemia, 
personal and fa mily history of CAD); and levels 
of C-reactive protein (CRP), troponin T and 
N-terminal pro-B-type natriuretic peptide (NT-
proBNP). Pre-event medication, in-hospital and 
follow-up therapy were also recorded.
Informed consent was obtained for all subjects 
enrolled, and the study was approved by the local 
Ethical Committee.
Study protocol and sampling
A longitudinal follow-up of all patients in the 
AMI group was carried out on three different 
occasions. For all AMI patients blood samples 
were obtained from the right femoral artery before 
the administration of IIb/IIIa inhibitors and 
angioplasty (Day 0). Additionally, blood samples 
were obtained by venous puncture two (Day 2) 
and 40 (Day 40) days after the initial angioplasty 
intervention.
Blood samples were drawn into pyrogen-
free blood collection tubes with EDTA and 
immediately centrifuged at 2500 rpm for 10 
minutes. The plasma-EDTA was collected after 
centrifugation and placed on ice. Aliquots were 
stored in liquid nitrogen until analysis (no longer 
than 6 months).
Oxidized LDL (oxLDL) concentrations were 
determined using a commercial ELISA (Mer-
codia, uppsala, Sweden). Each sample was 
assayed in duplicate; the intra-assay variation 
among the duplicates for all samples was <10%. 
oxLDL concentrations were expressed in u/l.
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variations in mean slopes between time points 
studied.
Table II. Biochemical data and inflammatory markers in 





Day 0 Day 2 Day 40
Lipid profile
TC (mg/dl) 192±6 199±7 b 169±8 b 152±6 b
LDL-C 
(mg/dl)
123±6 133±6 b 103±6 b 89±5 b
HDL-C 
(mg/dl)
54±2 40±2 b 37±3 b 37±2 b
TG (mg/dl) 74±5 113±9 b 104±6 b 131±14 b
oxLDL (u/l) 57±5 92±6 a 81±6 a,c 57±5 c,d
Inflammatory marker




90±2 177±10 b 137±8 b 118±7 b
Albumin 
(g/dl)
3.9±0.1 3.4±0.1a 3.2±0.1 a 3.9±0.1
Troponin T 
(ng/ml) 0.01±0.0 2.25±0.72 
a 4.15±0.83 a,c 0.05±0.03c,d
N-BNP 
(pg/ml)
38±6 663±128 a 1843±266 a,c 781±103 a,c,d
CRP: C-reactive protein; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-
density lipoprotein cholesterol; N-BNP:  N-terminal pro-B-type natriuretic peptide; TC: 
total cholesterol; TG: triglycerides. Data are expressed as mean ± SE. a: p<0.05 vs. REF 
group; b: not compared (see text); c: p<0.05 vs. AMI group at day 0; d: p<0.05 vs. AMI 
group at day 2.
To evaluate the possible influence of drug 
intake on oxLDL concentrations, the 12 AMI 
patients who were not taking any kind of pre-
event medication were compared to the remaining 
patients. oxLDL levels were not statistically 
different (p=0.245) between the two groups. 
To further evaluate the possible influence of 
drug therapy on serial changes in oxLDL, pre-
event, in-hospital and follow-up medication 
data were categorized and added to the linear 
mixed effects models as covariables. None of 
the drugs administered before or after admission 
significantly influenced changes in oxLDL 
concentrations over time (data not shown). 
Associations with coronary artery disease 
severity
The linear mixed effect model used to describe 
mean oxLDL decrease over time was also tested 
including number of diseased vessels, culprit 
vessel and biochemical indicators such as CRP, 
troponin T and NT-pro BNP as covariables. No 
associations were found between serial changes 






Gender, F/M 7/18 9/41
Age (yrs) 44±2 60±2 a
BMI (kg/m2) 25±0.5 27±0.5
Waist perimeter (cm) 88±2 97±2 a
Systolic BP (mmHg) 124±2 122±4
Diastolic BP (mmHg) 72±2 72±2
Ejection fraction (%) - 51±2
Risk factors and comorbidity
Hypertension, n (%) 0 (0) 29 (57) a
Smoking, n (%) 0 (0) 25 (49) a
Dyslipidemia, n (%) 9 (36) 28 (55)
Diabetes, n (%) 0 (0) 13 (26) a
Abdominal obesity, n (%) 1 (4) 14 (28) a
Family history of CAD, n (%) 0 (0) 8 (18)
BMI: body mass index; BP: blood pressure. Values are expressed as mean ± SE, except 
otherwise indicated. a p<0.05 vs. REF reference group. AMI: acute myocardial infaction 
group.
Forty-seven percent of AMI patients had 
multivessel disease. The culprit vessel was the 
left anterior descending coronary artery (LAD) in 
25 patients, the right coronary artery (RCA) in 
17, and the left circumflex artery (LCX) in only 
8 patients.
Lipid and glucose data obtained for the two 
study groups could not be directly compared as 
fasting blood tests were only performed for REF 
individuals (Table II). Maximum values of CRP 
(an acute phase inflammatory indicator), NT-
proBNP and troponin T (markers of ventricular 
failure and myocardial damage) were observed at 
Day 2.
Since the assumption behind longitudinal 
analysis is that missing data are missing 
completely at random, the missing information 
was examined in detail. Patients who died (n=3) or 
were lost to follow-up (n=10) did not significantly 
differ from other patients in terms of age, risk 
factors, comorbidity or clinical characteristics 
(data not shown).
Longitudinal variations in plasma oxLDL
At the onset of myocardial infarction (Day 
0) plasma oxLDL concentrations were markedly 
increased compared to the values obtained for the 
reference group (Table II). The levels decreased 
significantly over time, reaching values similar 
to the REF group 40 days after infarction (Table 
II). Modeling these changes showed significant 
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are usually associated with a favorable prognosis, 
contrasting with LAD-associated conditions that 
can compromise large areas of myocardium.
Although it is widely accepted that oxLDL 
exists in blood, the mechanisms and kinetics 
governing oxLDL in the circulation remain 
unclear(4), especially the question of where 
oxidative modification of LDL takes place(6). 
Several authors have proposed that LDL 
oxidation may not preferentially occur in 
blood(3-4). The plasma oxLDL associated with 
CAD may derive from the arterial wall by back-
diffusion(3) or oxidative modification of LDL by 
leukocytes at sites of plaque rupture(1,6). The high 
levels of oxLDL at AMI onset (Day 0) observed 
in the present study support the hypothesis that 
an increase in oxLDL levels is associated with 
plaque instability, as previously suggested(2,5,7-8).
The inflammatory process associated with 
plaque rupture and ischemia/reperfusion injury 
promotes the generation of excessive pro-
oxidants, disrupting the antioxidant/oxidant 
balance in blood(7). The gradual reduction in 
oxLDL concentrations with clinical stabilization 
observed in this study could be partially due to 
changes in the redox balance, through either an 
increase in the activity of antioxidant systems 
or a reduction in oxidant levels, as proposed by 
Nakuro et al.(7).
There are few studies reporting oxLDL 
measurements at the onset of AMI or a few days 
afterwards(5,7-8). Longitudinal data for oxLDL in 
AMI is limited(9), but overall a good agreement 
was found between data sets at discrete time 
points obtained in this work with similar disease 
conditions reported by other authors. Enhanced 
oxLDL levels have been reported in CAD 
patients in different clinical situations such 
as myocardial infarction, stable and unstable 
angina, or transplantation(2-3,5,10).
To the best of our knowledge this is the first 
study reporting an association between circulating 
oxLDL decreases and the LCX culprit vessel in 
AMI patients. The very high levels of oxLDL in 
patients with LAD or RCA as culprit vessel and 
the low levels of oxLDL in LCX patients suggest 
that oxLDL may be associated with CAD severity 
and possibly with lesion characteristics that 
depend on the infarct-related artery. The above 
findings are consistent with the hypothesis that 
oxLDL has an important role in the atherosclerotic 
process, both as an inflammatory mediator and 
in oxLDL and the biochemical markers studied 
(p=0.204, p=0.092 and p=0.114, respectively) or 
the number of diseased vessels (p=0.973).
However, examining serial variations in 
oxLDL by culprit vessel showed that patients 
with LCX as culprit had the lowest oxLDL 
levels (Figure 1). Although a general tendency 
for oxLDL to decrease with time was observed 
in all cases, low oxLDL levels were consistently 
associated with patients having LCX as culprit 
vessel (p=0.046) compared to those with LAD 
or RCA. The model significance was correlated 
particularly strongly with oxLDL concentrations 
at Day 0 (Figure 1).
Figure 1. Influence of the culprit vessel (LAD – squares; RCA 
– circles; and LCX -  triangles) on oxLDL concentrations 
(mean, SE) from myocardial infarction onset (Day 0) until 
Day 40. Significances (p<0.05) vs. LAD (a) and RCA (b) at 
each time point are indicated.
 
DISCUSSION
The present study demonstrates that plasma 
oxLDL levels were markedly elevated at MI 
onset before therapeutic intervention and 
decreased shortly afterwards (Day 2), continuing 
to fall 40 days later. The decline in oxLDL 
concentrations with time was significant and 
these serial changes were influenced by culprit 
lesion location. AMI patients with the LCX 
artery as culprit vessel had the lowest oxLDL 
concentrations, particularly at MI onset, unlike 
patients in whom the cause of infarction was the 
LAD or RCA. Thus, these results suggest that 
the increase in oxLDL concentration is related to 
CAD severity, as conditions such as LCX lesions 
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as a product of imbalance between pro- and 
anti-oxidant systems. Plaque composition and 
activity have been associated with enhanced 
inflammatory indices and different lesion 
characteristics in the three coronary arteries(11). 
Supplementary studies, using different imaging 
techniques for lesion assessment, are therefore 
essential to verify this hypothesis. New imaging 
approaches with histological characterization 
based on backscattered ultrasound may bring new 
insights in lesion characteristics and complexity. 
This will be of the utmost importance to identify 
the degree of dependence of circulating oxLDL 
levels on culprit vessel and lesion type and 
thereby validate its usefulness as a marker of 
plaque instability.
A major limitation of this study is the limited 
number of subjects enrolled so far in some 
subgroups. Large-scale studies involving more 
patients may be needed to support the results 
obtained. Nevertheless, serial changes in oxLDL 
values in AMI patients and their association 
with the infarct-related artery suggest that this 
marker may be useful to broaden understanding 
of plaque instability and to improve evaluation of 
coronary artery disease severity.
Rev Port Cardiol
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